Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

Califf

, Nalubola

. 2017. FDA's science-based approach to genome edited products. FDA Voice, January 18. Available at: http://blogs.fda.gov/fdavoice/index.php/2017/01/fdas-science-based-approach-to-genome-edited-products/ (accessed February 9, 2017).

Tribble

, Lupkin

. 2017. Drugmakers manipulate orphan drug rules to create prized monopolies. Kaiser Health News, January 17. Available at: http://khn.org/news/drugmakers-manipulate-orphan-drug-rules-to-create-prized-monopolies/ (accessed February 8, 2017).

AbbVie. 2017. AbbVie reports full-year and fourth-quarter 2016 financial results. Available at: https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2016-financial-results.htm (accessed February 8, 2017).

Tribble and Lupkin (2017). Drugmakers manipulate orphan drug rules to create prized monopolies. Kaiser Health News, January 17. Available at: http://khn.org/news/drugmakers-manipulate-orphan-drug-rules-to-create-prized-monopolies/ (accessed February 8, 2017).

Fidler

. 2017. Investors sour on data debut for Dimension's hemophilia gene therapy. Xconomy, January 31. Available at: www.xconomy.com/boston/2017/01/31/investors-sour-on-data-debut-for-dimensions-hemophilia-gene-therapy/# (accessed February 7, 2017).

Dimension Therapeutics. 2017. Dimension announces interim topline results from ongoing Phase 1/2 clinical program for DTX101, Dimension's lead AAV product candidate in development for adult patients with moderate/severe to severe Hemophilia B. Available at: http://investors.dimensiontx.com/phoenix.zhtml?c=254192&p=irol-newsArticle&ID=2240877 (accessed February 8, 2017).

Biogen. 2016. U.S. FDA approves Biogen's SPINRAZA™ (nusinersen), the first treatment for spinal muscular atrophy. Available at: http://media.biogen.com/press-release/neurodegenerative-diseases/us-fda-approves-biogens-spinraza-nusinersen-first-treatment (accessed February 7, 2017).

AveXis. 2016. AveXis to use intended commercial GMP product in SMA Type 2 study. Available at: http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle_pf&ID=2231235 (accessed February 9, 2017).

Mako Research. 2016. AveXis: more excuses and more delay, while superior competing drug receives approval for shipment Next week. Seeking Alpha, December 27. Available at: http://seekingalpha.com/article/4032836-avexis-excuses-delay-superior-competing-drug-receives-approval-shipment-next-week (accessed February 9, 2017).